Story preview
Topics in this story
Continue reading on the publisher site for the full article.
Read on publisher →Healthcare Digital
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
5
in the last 3 days
First reported
28 hr. ago
4 outlets since
Countries
4 other outlets reported this story in the last 3 days.
Teva’s Weltruza was “developed with the patient in mind from day one,” says Chris Fox, Executive VP, as the company advances its “Pivot to Growth” strategy
Teva said it is debuting the drug to overcome adherence issues with an oral counterpart and improve symptom outcomes.
Teva wins FDA nod for monthly olanzapine shot that ends monitoring Monthly subcutaneous shot from Teva leverages MedinCells Stabilitec to ease dosing and remove post‑injection observation